PhD. 1996 Rheumatology Unit, Royal Postgraduate Medical School
Studies of a human monoclonal antiphospholipid antibody
1996-2005 Department of Haematology, University of Cambridge. DNA based idiotypic vaccination as a treatment for follicular lymphoma, production of clinical grade patient specific DNA vaccines for a Phase I/II clinical trial. Prime-boost vaccination (DNA/MVA) as a treatment for follicular lymphoma. Molecular adjuvants and DNA vaccination. The use of DNA vaccination to produce domain/fragment specific antibodies. Antibody engineering.
2002-05 Prime-Boost Vaccines For Chronic Myelogenous Leukaemia, The Lymphoma and Leukemia Society. Principal Investigator, with Dr W. H. Ouwehand, Prof. J. Melo and Dr J. Apperly $373,125
2001-04 Development of recombinant human antibodies against B7.1 (CD80) for immune tolerisation in haematopoietic stem cell transplantation, with Dr N.A. Watkins, Dr, Dr C. Navarrete and Prof. K. Wood, National Blood Service, 135,42
2001-03 DNA based idiotypic vaccination in Follicular Lymphoma, with Dr W.H. Ouwehand, Cancer Research Campaign/Cancer Research UK, 63,600
1998-2002 DNA based idiotypic vaccination in Follicular Lymphoma, with Dr W. H. Ouwehand, with Prof. Freda K. Stevenson and Prof. T. J. Hamblin, National Blood Service, 243,318
Specificity of antibodies in follicular lymphoma. Fine specificity and origins of antibodies associated with heparin induced thrombocytopenia.
Antibody engineering including conversion of Stro1 and anti PF4/heparin monoclonal antibodies to recombinant fragments, incorporation of photoactivable cross linking agents into antibody binding sites and modifications to express naturally biotinylated antibodies that can be combined with streptavidin to generate tetramers.